Adage Capital Partners
SMMT icon

Adage Capital Partners’s Summit Therapeutics SMMT Stock Holding History

Adage Capital Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-538,000
Closed -$10.4M – 942
2025
Q1 		$10.4M Buy
+538,000
New +$10.8M 0.02% 577

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Adage Capital Partners's SMMT Position: Q2 2025 in Review

Adage Capital Partners sold out of Summit Therapeutics (SMMT) in Q2 2025, closing a stake of 538,000 shares — an estimated $10.4M sold.

Adage Capital Partners first reported a position in SMMT in Q1 2025 and held it in 1 quarter. The position peaked at $10.4M in Q1 2025. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • Adage Capital Partners reported no remaining Summit Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Adage Capital Partners sold 538,000 Summit Therapeutics shares in Q2 2025, an estimated $10.4M.
  • Adage Capital Partners first reported a position in Summit Therapeutics in Q1 2025 and held it in 1 quarter.
  • Adage Capital Partners's Summit Therapeutics position peaked at $10.4M in Q1 2025.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Adage Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.